Castle Biosciences' intrinsic value is 85% higher than its analyst price target. Using a Discounted Cash Flow model, the company's future cash flows are projected to be US$1.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Castle Biosciences, Inc.'s (NASDAQ:CSTL) Intrinsic Value Is Potentially 95% Above Its Share Price
